Catalyst

Slingshot members are tracking this event:

Cara (CARA) Presents on CR845 in Pruritus and Other Chronic Kidney Disease Patients Undergoing Hemodialysis at the American Society of Nephrology's Annual Meeting

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CARA

100%

Additional Information

Clinical Data CR845, a Novel Kappa Opioid Receptor Agonist, Reduces Moderate-to-Severe Pruritus and Improves Quality of Life in Chronic Kidney Disease Patients Undergoing Hemodialysis ***Full poster in the source link****
http://files.shareho...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 07, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pruritus, Ckd, Chronic Kidney Disease Patients, Cr845, Hemodialysis